Patient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration for Evaluating Biosimilar Uptake?
Gabriel Horta-BaasPublished in: Patient related outcome measures (2022)
There is scarce literature surrounding the impact of biosimilars in PROMs, especially in open-label studies. In real-life studies, biosimilars have a higher discontinuation rate than reference products. TNFis biosimilars treatment efficacy in RA depends on disease activity and other factors such as PtGA and fatigue. The nocebo effect is the best explanation for biosimilar's discontinuation.
Keyphrases
- patient reported outcomes
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- open label
- juvenile idiopathic arthritis
- case control
- systematic review
- clinical trial
- interstitial lung disease
- study protocol
- sleep quality
- radiation therapy
- physical activity
- depressive symptoms
- phase iii
- phase ii study